FDA raises concerns over unapproved GLP-1 drugs including retatrutide
The agency's warning centers on products sold for weight loss that have not been approved for any use.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 2 02:17 ETSource: www.polskieradio.pl
The wire
- 01The report describes FDA concern about unapproved GLP-1 products, naming retatrutide, being used for weight loss.
- 02Retatrutide remains an investigational Lilly molecule, so any consumer-facing supply is outside the approved channel and unverified for identity, purity or dose.
- 03Details of any formal agency action, such as warning letters or import alerts, are not specified in the report.
From the source
Read at polskieradio.plfda concerns unapproved glp-1 drugs used for weight loss retatrutide
